Pacific Biosciences of California, Inc. Increase Decrease In Operating Lease Liability
Pacific Biosciences of California, Inc. (PACB) reported Increase Decrease In Operating Lease Liability of $2.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was $1.47M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was $1.43M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $1.38M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $1.07M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for fiscal 2025 was $723.00K.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for fiscal 2024 was -$11.92M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for fiscal 2023 was -$8.76M.
- Pacific Biosciences of California, Inc. increase decrease in operating lease liability for fiscal 2022 was -$7.72M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.89M 10-Q · filed 2026-08-06 | $4.28M derived: sum of 3 quarters · filed 2026-08-06 | $5.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.43M 10-Q · filed 2026-05-08 | $2.81M derived: sum of 2 quarters · filed 2026-05-08 | $3.88M derived: sum of 3 quarters · filed 2026-05-08 | $3.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.45M derived: sum of 2 quarters · filed 2026-02-25 | $2.34M derived: sum of 3 quarters · filed 2026-08-06 | $723.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $957.00K derived: sum of 2 quarters · filed 2026-08-06 | -$661.00K 10-Q · filed 2025-11-06 | -$3.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.73M 10-Q · filed 2026-08-06 | -$4.40M derived: sum of 3 quarters · filed 2026-08-06 | -$8.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.62M 10-Q · filed 2026-05-08 | -$4.29M derived: sum of 2 quarters · filed 2026-05-08 | -$8.79M derived: sum of 3 quarters · filed 2026-05-08 | -$11.16M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$7.17M derived: sum of 2 quarters · filed 2026-02-25 | -$9.54M derived: sum of 3 quarters · filed 2026-02-25 | -$11.92M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$6.88M derived: sum of 2 quarters · filed 2025-11-06 | -$9.25M 10-Q · filed 2025-11-06 | -$11.62M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$4.75M 10-Q · filed 2025-08-07 | -$7.11M derived: sum of 3 quarters · filed 2026-02-25 | -$9.39M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$2.38M 10-Q · filed 2025-05-12 | -$4.74M derived: sum of 2 quarters · filed 2026-02-25 | -$7.02M derived: sum of 3 quarters · filed 2026-02-25 | -$9.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$4.64M derived: sum of 2 quarters · filed 2026-02-25 | -$6.79M derived: sum of 3 quarters · filed 2026-02-25 | -$8.76M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.43M derived: sum of 2 quarters · filed 2024-11-12 | -$6.40M 10-Q · filed 2024-11-12 | -$8.21M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$4.11M 10-Q · filed 2024-08-09 | -$5.93M derived: sum of 3 quarters · filed 2025-03-17 | -$8.01M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$1.97M 10-Q · filed 2024-05-09 | -$3.79M derived: sum of 2 quarters · filed 2025-03-17 | -$5.86M derived: sum of 3 quarters · filed 2025-03-17 | -$7.81M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$3.89M derived: sum of 2 quarters · filed 2025-03-17 | -$5.84M derived: sum of 3 quarters · filed 2025-03-17 | -$7.72M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$4.02M derived: sum of 2 quarters · filed 2023-11-03 | -$5.91M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$3.83M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | -$1.88M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |